Compare the Best CROs for Biotech Companies

Who this guide is for

This guide is for founders, clinical operations heads and programme leads at emerging and small biotechs choosing a contract research organisation, often for the company's first outsourced trial. You may have a lean in-house team, a funding milestone riding on a clean readout, and investors watching how the study is run. The ranked list above is a starting point drawn from the Clinical Vendor Compare directory, not a verdict on which vendor suits your molecule, phase or budget; not every ranked profile describes a biotech fit, so check each record. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score. The sections below help you weigh full-service, boutique and specialist models, sharpen your RFP and spot warning signs.

What a CRO for biotech sponsors does — and when you need one

A contract research organisation runs some or all of a clinical trial for the sponsor: feasibility, site selection, submissions, monitoring, project management, data management, biostatistics, pharmacovigilance and medical writing. For a biotech it supplies capacity the company has not yet built, but not accountability. Under ICH E6(R3) the sponsor keeps ultimate responsibility for trial conduct and data reliability, and must oversee any activity it transfers to a service provider in proportion to risk.

Adjacent vendors cover narrower ground. Functional service providers place staff inside the sponsor's own processes, which a young biotech may not yet have. Biometrics specialists handle data and statistics only; site networks focus on enrolment; regulatory consultancies prepare submissions without running the study. A boutique CRO UK biotechs often consider sits between these: a smaller full-service team with senior people on the account, but a thinner bench and a narrower country footprint.

Typical triggers are a first-in-human study, sites in a new region, a protocol needing expertise you lack, or a financing round that fixes a readout date your team cannot meet alone.

How to evaluate a CRO for biotech sponsors

Fit for your size and stage

Ask which current projects resemble yours in phase, indication and budget, and who makes decisions on them. A CRO whose core business is large global programmes may give a small study to a junior team. A small CRO UK sponsors shortlist may offer senior attention but struggle to absorb an amendment that suddenly widens the site footprint. Ask both kinds how they would handle that scenario, and how many other studies the proposed team is carrying at the same time.

Team continuity and seniority

The people who pitch are not always the people who deliver. Ask to meet the proposed project manager, lead monitor and medical monitor before you sign, and ask for the staffing turnover policy and how handovers are documented. Write named key personnel into the contract, with a right to approve replacements and a defined handover period.

Therapeutic and phase depth

Indication experience shapes feasibility, endpoint handling and site relationships. Request anonymised examples of comparable studies, a sample monitoring plan for your indication and investigator references. For early-phase work, ask how dose-escalation decisions and safety review committees are supported.

Regulatory route and geography

A CRO for biotech UK programmes should explain how it handles combined review by the MHRA and a research ethics committee through IRAS, including the UK clinical trials regulations that took effect in 2026. If you will add EU sites, ask about submissions under Regulation (EU) No 536/2014 through CTIS; if a US filing is planned, ask who prepares the IND content. Confirm which countries the CRO staffs directly and where it relies on partners.

Support for sponsor oversight

ICH E6(R3) expects risk-proportionate quality management built around critical-to-quality factors, and documented sponsor oversight of service providers. Ask for a sample oversight plan, the key risk indicators the CRO reports, how often you see them, and how issues escalate. Check that you will have direct, read access to the trial master file and the EDC rather than waiting for summaries.

Data, systems and ownership

Ask which EDC, eTMF and safety systems will be used, how they are validated, and how electronic records meet 21 CFR Part 11 if data will support an FDA submission. If you expect to file, ask whether datasets will be delivered in CDISC SDTM and ADaM. Confirm in writing that the data are yours and how they transfer if the relationship ends.

Commercial transparency

Ask for the budget assumptions behind every line, how pass-through costs are handled, and the change-order process including who can approve one. A lean biotech should link payment milestones to delivered outcomes and to the timing of its own funding, not to calendar dates alone.

CROs for biotech sponsors at a glance

The table lists vendors in the directory whose profiles mention biotech, emerging or mid-size work in their stated fit, scale or positioning. Treat it as a scan aid for building a long list, not as a ranking of quality.

Every field comes from each vendor's Clinical Vendor Compare profile. Most vendors profiled below describe specialist or mid-size programmes; some list a generalist therapeutic scope, while others are narrow, such as CNS or dermatology. Footprints range from global to a single region, so a UK sponsor planning European sites should check geography before service model. The two Everest listings carry matching profiles.

Vendor profiles

Parexel

A full-service CRO with a global footprint and United States headquarters, covering Phase I to Phase IV in oncology, neuroscience, rare disease and generalist work across large and mid-size global programmes. Its stated best fit is programmes with heavy regulatory complexity and global filings; recorded strengths are regulatory depth and consultative support. Where to probe: the profile notes pricing pressure for smaller biotech budgets, so ask how a smaller study would be staffed.

Worldwide Clinical Trials

A full-service CRO with a global footprint and United States headquarters, covering Phase I to Phase III in neuroscience, oncology, rare disease and internal medicine. Its best fit is biotech or specialist programmes wanting high-touch support, therapeutic alignment and flexible outsourcing structures, with therapeutic specialisation and senior expert access among its strengths. Where to probe: public proof points are noted as mostly self-described, so ask for sponsor references.

Clinilabs

Recorded as a full-service CRO working on a specialist CRO model, headquartered in the USA with a North America and global footprint. Its focus is CNS, phases are listed as mixed, and its scale is specialist and mid-size programmes. The recorded strength is CNS clinical trials and imaging. Where to probe: ask which countries the team monitors directly, how imaging reads are quality-controlled, and who handles UK and EU submissions.

Datapharm Australia

A specialist CRO offering a full-service model, headquartered in Australia with an Asia Pacific and global footprint, covering Phase I to Phase IV with a generalist scope. Its stated best fit is sponsors needing end-to-end outsourced study delivery, with breadth, delivery coverage and operational scale as strengths. Where to probe: the profile marks it as a weaker match for teams seeking highly niche or ultra-boutique support, so test how much senior attention you would receive.

Lindus Health

A full-service CRO headquartered in the United Kingdom with a North America, Europe and global footprint, mixed phases and a generalist scope, focused on modern, digitally enabled mid-market studies. Its stated best fit is sponsors prioritising start-up speed, digital execution and a contemporary operating model, and the profile records a fit for emerging biotech teams. Where to probe: ask how its start-up approach would apply to your indication, and request comparable references.

SofPromed

A specialist CRO with a full-service model, headquartered in Spain with a global footprint and Phase I to Phase IV coverage across oncology, cardiovascular, metabolic, CNS, dermatology, infectious disease and respiratory. Its stated best fit is end-to-end outsourced study delivery, with breadth, delivery coverage and operational scale as strengths. Where to probe: the profile flags it as a weaker match for highly niche or ultra-boutique needs, so ask who your day-to-day contacts would be.

TKL Research

Recorded as a full-service CRO on a specialist CRO model, headquartered in the USA with a North America footprint and Phase I to Phase III coverage in dermatology and cosmetics. Its stated fit is mid-size programmes needing full-service capability with clear sponsor-facing accountability, and the profile notes a credible public delivery story across North America. Where to probe: a UK biotech should confirm whether UK or European sites are possible or would need a partner.

Everest Clinical Biometrics

A specialist CRO with a full-service model, headquartered in Canada with a North America, Europe, Asia and global footprint and Phase I to Phase IV coverage across a generalist scope. Its stated best fit is programmes needing statistics, programming, data management or analytics, with statistical rigour, programming capacity and data quality as strengths. Where to probe: the profile notes it may need integration with sponsor or CRO systems and standards, so agree data transfer specifications early.

Everest Clinical Research

This listing carries the same profile: a specialist CRO with a full-service model, headquartered in Canada, with a North America, Europe, Asia and global footprint, Phase I to Phase IV coverage and a best fit for programmes needing statistics, programming, data management or analytics. Where to probe: because the two listings match, confirm which entity would hold your contract and which services each delivers.

Croissance Clinical Research

A full-service CRO headquartered in India with an APAC footprint, mixed phases and a generalist scope, describing specialist and mid-size Asia programmes. Its stated fit is mid-size programmes needing full-service capability and clear sponsor-facing accountability, and the profile notes a credible public delivery story across Asia. Where to probe: a UK biotech adding Asian sites should ask how oversight works across time zones and how data transfers meet UK GDPR.

Engagement and pricing models

Many emerging biotechs buy a full-service model: one CRO, one contract, one budget. Budgets are usually built from units such as sites activated, monitoring visits and patients enrolled, with payments tied to milestones. Functional service provision, paying for dedicated staff on an FTE basis, suits sponsors with mature processes and is rarely a first step. Hybrid models are common: a CRO runs operations while a biometrics specialist handles data management and statistics, giving you control of the data but making you the integrator.

Cost is driven by country and site count, monitoring intensity, protocol complexity, recruitment difficulty, the number of data and safety deliverables, and pass-through costs such as investigator fees and central laboratories. Change orders are where small budgets erode. A full-service CRO offers depth and single-point accountability but may price in overhead a small study does not need; a boutique offers senior attention but less capacity if the study grows.

Questions to put in your RFP

• Which current studies resemble ours in phase, indication and sponsor size, and can we speak to those sponsors?
• Who will our project manager, lead monitor and medical monitor be, and will they be named contractually?
• How will you support our oversight obligations under ICH E6(R3), and what will a routine oversight report contain?
• Which critical-to-quality factors do you see in our protocol, and how would your monitoring address them?
• Who prepares our MHRA and ethics application through IRAS, and how would you handle EU sites through CTIS?
• Which countries do you staff directly, and where would you use partners or subcontractors?
• What assumptions sit behind each budget line, and what triggers a change order?
• How are pass-through costs invoiced, and can payment milestones align with our funding tranches?
• Which EDC, eTMF and safety systems will you use, and will we have direct access?
• How will data and documents transfer if we change provider, and in what format?

Due-diligence red flags

• The bid team cannot name the delivery team, or refuses to commit key personnel in the contract.
• A budget far below other bids, with no stated assumptions.
• Vague change-order terms, or scope questions deferred until later.
• The CRO cannot describe how it will support your sponsor oversight under ICH E6(R3).
• You would see only periodic summaries rather than direct access to the TMF and EDC.
• Country coverage depends heavily on unnamed subcontractors.
• References are offered only from large pharmaceutical sponsors, never from biotechs at your stage of development.
• Data ownership, exit assistance or record retention are missing from the draft contract.
• Feasibility promises fast enrolment without site-level evidence for your indication or patient population.

Shortlist on Clinical Vendor Compare

Start in the vendor directory and filter by therapeutic area, phase and geography to build a long list that mixes full-service, boutique and specialist options. Use compare to set profiles side by side and check footprint, service model and stated best fit. When you are ready to approach vendors, the sponsor RFP page helps you structure the request around the questions above. If you have already worked with any CRO, please write a review: published reviews are what give other biotech teams a real basis for comparison.